Skip to main content
SpringerLink
Log in

Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

The lipophilic derivatives of the anticancer alkylating agent chlorambucil, chlorambucil-methyl, -isopropyl and -tertiary butyl esters, were synthesized and administered i.v. to anesthetized rats. Plasma and brain concentrations of these agents and of their active metabolites, chlorambucil and phenylacetic mustard, then were determined by high-performance liquid chromatography between 5 and 60 min. Whereas large amounts of chlorambucil-tertiary butyl ester entered and were maintained in brain, lower amounts of chlorambucil-isopropyl ester and no chlorambucil-methyl ester were found in brain. The comparative brain/plasma concentration-time integral ratios of the total active agents generated from chlorambucil-tertiary butyl, -isopropyl and -methyl esters were 0.85, 0.12 and 0.06, respectively, compared to a ratio of 0.02 for chlorambucil. In vitro alkylating activity of each ester was compared to that of equimolar chlorambucil, by reaction with 4-(p-nitrobenzyl)pyridine. Each ester possessed high intrinsic alkylating activity, equal to 38.4, 57.0 and 69.9% of chlorambucil activity, for the -tertiary butyl, -isopropyl and -methyl esters, respectively. Therefore each is an active antineoplastic agent irrespective of whether or not chlorambucil is regenerated. The rates of ester hydrolysis of these derivatives to chlorambucil were measured in fresh rat blood and in liver and brain homogenates at 37°C. Chlorambucil-methyl and -isopropyl esters were hydrolysed quickly within 30 s in blood and liver, whereas chlorambucil-tertiary butyl ester was more stable with half-lives of approximately 7 h and 2 h, respectively. All proved to be relatively stable in brain homogenate. Steric hindrance around the ester linkage of chlorambucil-tertiary butyl ester reduces its affinity to and rate of hydrolysis by plasma and liver esterases, and allows it to accumulate within the brain. Chlorambucil-tertiary butyl ester maintains high levels in brain despite rapidly declining plasma concentrations and, due to these favorable pharmacokinetics and to its intrinsic anticancer activity, it possesses promising characteristics for the treatment of malignant brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hildebrand J, 1985, Current status of chemotherapy of brain tumors. Progress in Experimental Tumor Research, 29, 152–166.

    Google Scholar 

  2. Kornblith PL, Walker MD and Cassady JR. Neurologic Oncology. Philadelphia, PA: J.B. Lippincott, 1987.

    Google Scholar 

  3. Walker MD, Green SB and Byar DP, 1980, Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New England Journal of Medicine, 303, 1323–1329.

    Google Scholar 

  4. DeVita VT, Carbone PP, Owens AB, Gold GL, Krant MJ and Edmonson J, 1965, Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Research, 25, 1876–1881.

    Google Scholar 

  5. Schabel FM, Johnston TP, McCaler GS, Montgomery JA, Laster WR and Skipper HE, 1963, Experimental evaluation of potential anticancer agents. VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia. Cancer, 23, 725–733.

    Google Scholar 

  6. Paoletti P, Knerich R, Adinolfi D, Butti G and Pezzotta S. Therapy for central nervous system malignant tumors. In: Gerosa MA, Rosenblum MA and Tridente G, eds. Brain Tumors: Biopathology and Therapy. Advances in the Biosciences, Vol. 58, pp. 223–235. Oxford: Pergamon Press, 1985.

    Google Scholar 

  7. Greig NH, 1984, Chemotherapy of brain metastases: current status. Cancer Treatment Reviews, 11, 157–186.

    Google Scholar 

  8. Greig NH, 1987, Optimizing drug delivery to brain tumors. Cancer Treatment Reviews, 14, 1–28.

    Google Scholar 

  9. Greig NH, Genka S and Rapoport SI, 1990, Delivery of vital drugs to the brain for the treatment of brain tumors. Journal of Controlled Release, 11, 61–78.

    Google Scholar 

  10. Rapoport S.. Blood-Brain Barrier in Physiology and Medicine. New York: Raven Press, 1976.

    Google Scholar 

  11. Reese T and Karnosvsky M, 1967, Fine structural localization of a blood-brain barrier to exogenous peroxidase. Journal of Cell Biology, 34, 207–217.

    Google Scholar 

  12. Greig NH. Brain tumors and the blood tumor barrier. In: Neuwelt EA, ed. Implications of the Blood-Brain Barrier and its Manipulation, Vo1. 2, Clinical Studies, pp. 77–106. New York: Plenum Press, 1989.

    Google Scholar 

  13. Greig NH. Drug delivery to the brain by blood brain barrier circumvention and drug modification. In: Neuwelt EA, ed. Implications of the Blood Brain Barrier and its Manipulation, Vol. 1, Basic Science Aspects, pp. 311–367. New York: Plenum Press, 1989.

    Google Scholar 

  14. Carter SK, Bakowski MT and Hellmann K. Chemotherapy of Cancer, 3rd edn. New York: Wiley Medical, 1987.

    Google Scholar 

  15. Dorr R and Fritz W. Cancer Chemotherapy Handbook. London: Kimpton, 1980.

    Google Scholar 

  16. Greig NH, Sweeny DJ and Rapoport SI, 1988, Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat. Cancer Chemotherapy and Pharmacology, 21, 1–8.

    Google Scholar 

  17. Krogsgaard-Larsen P and Christensen A, 1979, GABA agonists. Synthesis and structure-activity studies on analogues of isoguvacine and THIP. European Journal of Medical Chemistry, 14, 157–164.

    Google Scholar 

  18. Sinkula A and Yalkowsky S, 1975, Rationale for design of biologically reversible drug derivatives: prodrugs. Journal of Pharmacological Science, 64, 181–210.

    Google Scholar 

  19. Ross WCJ. Biological Alkylating Agents; fundamental chemistry and the design of compounds for selective toxicity. London: Butterworths, 1962.

    Google Scholar 

  20. Epstein J, Rosenthal RW and Ess RJ, 1955, Use of p-(4-nitrobenzyl)pyridine as analytical reagent for ethylenimines and alkylating agents. Analytical Chemistry, 27, 1435–1439.

    Google Scholar 

  21. Freidman OM and Boger E, 1961, Chlorimetric estimation of nitrogen mustard in aqueous media. Analytical Chemistry, 33, 906–910.

    Google Scholar 

  22. Greig NH, Stahle PL, Shetty HU, Genka S, John V, Soncrant TT and Rapoport SI, 1990, High performance liquid chromatography analysis of chlor- ambucil-tertiary butyl ester and its active metabolites, chlorambucil and phenylacetic mustard, in plasma and tissue samples. Journal of Chromatography, 534, 279–286.

    Google Scholar 

  23. Greig NH, Fredericks WR, Holloway HW, Soncrant TT and Rapoport SI, 1988, Delivery of interferonalpha to brain by transient osmotic blood-brain barrier modification in the rat. Journal of Pharmacology and Experimental Therapy, 245, 581–586.

    Google Scholar 

  24. Wagner JG. Fundamentals of Clinical Pharmacokinetics. Hamilton IL: Drug Intelligence Publications, 1975.

    Google Scholar 

  25. Greig NH. Drug delivery to brain tumors. In: Magrath I, ed. New Directions in Cancer Treatment, pp. 259–280. New York: Springer-Verlag, 1989.

    Google Scholar 

  26. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR and Rapoport SI, 1990, Brain uptakes and anticancer activities of vincristine and vinblas tine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemotherapy and Pharmacology, 26, 263–268.

    Google Scholar 

  27. Greig NH, Momma S, Sweeney DJ, Smith QR and Rapoport SI, 1987, Facilitated transport of melphaIan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Research, 47, 1571–1576.

    Google Scholar 

  28. Bradbury MWB. The Concept of a Blood-Brain Barrier. Chichester: John Wiley, 1979.

    Google Scholar 

  29. Rapoport SI and Levitan H, 1974, Neurotoxicity of X-ray contrast media: relation to lipid solubility and blood-brain barrier permeability. American Journal of Roentgenology, Radium Therapy and Nuclear Medicine, 122, 186–193.

    Google Scholar 

  30. Ehrsson H, Lonroth U, Wallin I, Ehrnebo M and Nilsson S, 1981, Degradation of chlorambucil in aqueous solution: influence of human albumin binding. Journal of Pharmacy and Pharmacology, 33, 313–315.

    Google Scholar 

  31. Godeneche D, Madelmont J, Moreau M, Plague R and Meyniel G, 1980, Comparative physico-chemical properties, biological effects, and disposition in mice of four nitrogen mustards. Cancer Chemotherapy and Pharmacology, 5, 1–9.

    Google Scholar 

  32. Greig N. Drug entry into brain and its pharmacologic manipulation. In: Bradbury MWB, ed. Physiology and Pharmacology of the Blood-Brain Barrier. Handbook of Experimental Pharmacology, Vol. 103, pp. 487–523. Heidelberg: Springer-Verlag, 1992.

    Google Scholar 

  33. Notari E, 1981, Prodrug design. Pharmacology Therapy, 14, 25–53.

    Google Scholar 

  34. Stella VJ, Charman WNA and Naringrekar VH, 1985, Prodrugs, do they have advantages in clinical practice? Drugs, 29, 455–473.

    Google Scholar 

  35. Higuchi T. Prodrug and drug delivery; an overview. In: Roche EB, ed. Bioreversible Carriers in Drug Design, Theory and Application, pp. 1–12. Oxford: Pergamon Press, 1987.

    Google Scholar 

  36. Jenner P and Testa B. Concepts in Drug Metabolism, Vol. 10. New York: Marcel Dekker, 1981.

    Google Scholar 

  37. Testa B and Jenner P. Drug Metabolism: chemical and biochemical aspects. New York: Marcel Dekker, 1976.

    Google Scholar 

  38. Dixon M and Webb E. Enzymes, 3rd edn. New York: Academic Press, 1979.

    Google Scholar 

  39. Soncrant TT, Holloway HW, Greig NH and Rapoport SI, 1989, Regional brain metabolic responsivity to the muscarinic cholinergic agonist arecoline is similar in young and aged Fischer-344 rats. Brain Research, 487, 255–266.

    Google Scholar 

  40. Shetty HU, Daly EM, Greig NH, Rapoport SI and Soncrant TT, 1991, Quantitation of arecoline in human plasma by automatic reaction control chemical ionization technique in ion trap mass spectrometer. Journal of the American Society of Mass Spectrometry, 2, 168–173.

    Google Scholar 

  41. Soncrant TT, Holloway HW and Rapoport SI, 1985, Arecoline-induced elevations of regional cerebral metabolism in the conscious rat. Brain Research, 347, 205–216.

    Google Scholar 

  42. Raffaele KC, Berardi A, Morris PP, Asthana S, Shapiro MB, Rapoport SI and Soncrant TT, 1991. Effects of long-term continuous infusion of the mus carinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type. Psychopharmacology Bulletin, 27, 315–319.

    Google Scholar 

  43. Soncrant TT and Nurnberger JI, 1989, Measuring cholinergic sensitivity: II. Arecoline effects on metabolic activity in pontine regions of rat brain. Biological Psychiatry, 25, 618–625.

    Google Scholar 

  44. Soncrant TT, Raffaele KC, Asthana S, Berardi A, Mooris PP and Haxby JV. Memory improvement without toxicity during chronic, low dose intraven ous arecoline in Alzheimer's disease. Psychopharmacolgy, in press.

  45. Suzuki F, Hayashi H, Ito S and Hayaishi O, 1987, Methyl ester of prostaglandin D2 as a delivery system of prostaglandin D2 into brain. Biochimica et Biophysica Acta, 917, 224–230.

    Google Scholar 

  46. Crevelling C, Daly J and Tokuyama T, 1969, Labile lipophilic derivative of norepinephrine capable of crossing the blood-brain barrier. Experientia, 25, 26–27.

    Google Scholar 

  47. Robinson PJ and Rapoport SI, 1990, Model for drug uptake by brain tumors: effects of osmotic treatment and of diffusion in brain. Journal of Cerebral Blood Flow, 10, 153–161.

    Google Scholar 

  48. Farmer PB, Foster AB, Jarman DR, Newell DR, Oddy DR and Kiburis JM, 1979, The metabolism of deuterated analogues of chlorambucil in the rat. Chemico Biological Interactions, 28, 211–220.

    Google Scholar 

  49. Newell DR, Calvert AH and Harrap KR, 1983, Studies on the pharmacokinetics of chlorambucil and prednimustine in man. British Journal of Clinical Pharmacology, 15, 253–258.

    Google Scholar 

  50. Ali-Osman F, Greig NH, John V, Lieberburg IM and Rapoport SI, 1991, Activity of chlorabucil-tertiary butyl ester against 2-chloroethylnitrosourea resistant human malignant glioma cell lines. Proceedings of the American Association of Cancer Research, 32, 318.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

    Shigeru Genka, Joseph Deutsch, Umesha H. Shetty, Paul L. Stahle, Stanley I. Rapoport & Nigel H. Greig

  2. Athena Neurosciences Inc., South San Francisco, CA, USA

    Varghese John & Ivan M. Lieberburg

  3. Department of Experimental Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Francis Ali-Osmant

Authors
  1. Shigeru Genka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Deutsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Umesha H. Shetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul L. Stahle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Varghese John
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ivan M. Lieberburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francis Ali-Osmant
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Stanley I. Rapoport
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nigel H. Greig
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genka, S., Deutsch, J., Shetty, U.H. et al. Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil. Clin Exp Metast 11, 131–140 (1993). https://doi.org/10.1007/BF00114971

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00114971

Keywords

Search

Navigation